Nafamostat Mesylate

甲磺酸萘莫司他

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameNafamostat Mesylate
Drug Alias Name萘莫司他甲磺酸盐Nafamostat MesilateNafamostat mesilate - Chong Kun DangNafabelltanDS-2319 +[8
ClassificationSmall molecules
Mechanisms of ActionSerine protease inhibitors
TargetsSerine protease
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)HemorrhageHemorrhagic Disorders +[7
Global Approved IndicationsDisseminated Intravascular CoagulationPancreatitis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved DateN/A
Country/TerritoryUnited StatesRussian FederationItaly +[6
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active IndicationsCoronavirus Disease 2019 (COVID-19)Hemorrhagic DisordersDisseminated Intravascular Coagulation +[5
Inactive IndicationsHemorrhagePancreatitis, Chronic

Other Information

ATC CodeB02AB
Related LinksWikipediaKEGG